Cell Microsystems is a private company providing innovative hardware and software platforms that automate and improve the process of isolating and analyzing single cells and clonal colonies. Its flagship CellRaft AIR System functions as an integrated cell sorter and colony picker, offering significant advantages in efficiency, traceability, and cell viability over traditional methods like limiting dilution and flow cytometry. The company serves a prestigious global customer base across academia and biopharma, with applications in cell line development, organoid research, microbiology, and cell therapy, positioning it as a key enabler in the rapidly growing fields of precision biology and regenerative medicine.
Cell TherapyDiagnostics
Technology Platform
The CellRaft platform: a microscale cell culture array combined with automated imaging and a gentle, air-based retrieval system for isolating single cells or colonies based on phenotypic observation over time.
Funding History
3
Total raised:$21M
Series B$10MBroadOak Capital Partners
Series A$8.5MBroadOak Capital Partners
Seed$2.5MUndisclosed
Opportunities
The rapid growth of the cell therapy market creates a direct need for efficient, traceable clonal cell line development, a core application of the CellRaft system.
Additionally, the expansion of complex 3D cell culture and organoid research presents a new frontier requiring gentle, image-based isolation tools that the platform is uniquely suited to provide.
Risk Factors
The company faces competition from established flow cytometry giants and emerging single-cell analysis platforms.
Market adoption risk exists as researchers may be slow to change entrenched workflows like limiting dilution.
Its growth is also tied to the funding and success of the cell therapy sector, a primary customer base.
Competitive Landscape
Cell Microsystems competes in the single-cell isolation and analysis space against major players like BD Biosciences and Beckman Coulter (flow cytometry/FACS) and other specialized platforms like Berkeley Lights' optoelectronic technology and microfluidic-based systems. Its key differentiation is the combination of long-term imaging within a shared culture environment followed by gentle, deterministic retrieval of viable cells.
